| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 20 | 10 | 80 | 250 | 0 |
| Sales Growth | +100.00% | -87.50% | -68.00% | unch | unch |
| Net Income | -1,450 | -1,580 | -1,340 | -620 | -670 |
| Net Income Growth | +8.23% | -17.91% | -116.13% | +7.46% | -28.85% |
Amarillo Biosciences (AMAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds twelve of Amarillo Biosciences' shares and has provided over million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Beh'et's disease, and opportunistic infections in patients who are HIV positive. In its twenty three year history, the company has invested nearly $thirty eight million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon.